SMAD3 and breast cancer: Mo et al. found that tRF-17 affects breast cancer cell invasion and migration by attenuating the THBS1-mediated TGF-β1/Smad3 signaling pathway in breast cancer cells, and may serve as a potential target for breast cancer therapy [76].